City-Wide Clinical Trials

A randomised, double-blind, parallel-group, placebo-controlled phase III study to evaluate the efficacy and safety of desmoteplase in subjects with acute ischemic stroke (DIAS 4) – The primary objective of this study is to evaluate the efficacy of desmoteplase 90 μg/kg versus placebo in terms of favourable outcome at Day 90 in subjects with acute ischemic stroke.
Active in: City Wide

Canadian Atherosclerosis Imaging Network (CAIN) – The main objective of this study is to gather imaging data of patients with atherosclerosis and to identify the pathobiology  of atherosclerotic disease as it pertains to the coronary and carotid circulations. This study will use an interdisciplinary network to understand the history of disease and its imaging biomarkers, as well as the links to patient outcomes.
Active in: City Wide

Canadian Fabry Stroke Screening Initiative (CFSSI): Frequency of Fabry’s Disease in an unselected group of Cryptogenic Stroke Patients – The aim of this study is to determine the frequency of Fabry’s disease in an unselected group of young patients (18-55 years of age) with acute cerebrovascular event not determined to be from other known causes.
Active in: City Wide

30-Day Cardiac Event Monitor Belt for Recording Atrial Fibrillation After a Cerebral Ischemic Event (EMRACE) – This randomized trial tests a newly developed cardiac monitoring belt that monitors heart rhythm for 30 days on 516 patients with cryptogenic embolic ischemic stroke or TIA within 6months and negative for history of atrial fibrillation or any post-stroke EKG and holter. Subjects were assigned randomly 1:1 to 30-day study monitor or repeat 24-hour Holter monitor (control).The study looks to find strokes that are caused by undiagnosed paroxysmal atrial fibrillation using the new monitor.
Active in: City wide

Weight Times – The purpose of this study is to demonstrate the feasibility and utility of capturing patient weight while on an ED stretcher and show that it can be successfully implemented for all hyperacute stroke patients without impeding speed of care and with accurate weighting and tPA dosing.Having an accurate measure of weight will allow more accurate dosage of tPa and will reduce the chance of negative side effects.
Active in: City Wide

Countdown Lights to Optimize Quality in acute Stroke (CLOQS) – This study will attach a large red LED stopwatch-clock to the patient’s stretcher at the moment of ED arrival to act as a constant visual reminder to all team members the urgency of the situation. We hypothesize that this simple visual cue will improve door-to-CT scan times and door-to-needle treatment times, and thus improve response to treatment and reduce adverse events.